You can read the full article at The impact of tirzepatide, a dual agonist targeting glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers related to nonalcoholic steatohepatitis (NASH) and fibrosis in type 2 diabetes mellitus (T2DM) patients was investigated
Rostom A, Dube C, Cranney A, Saloojee N, Sy R, Garritty C et al
Eligibility and other restrictions apply
Most patients find that consistent weekly dosing at a stable level resolves acute symptoms within 7-10 days, allowing comfortable progression toward therapeutic weight loss doses
Microdosing GLP-1s can be a helpful option for people who want a more personalized, gentle, and flexible approach to metabolic health
The relationship between these neurochemical markers and the kynurenine pathway underscores a promising avenue for future research, emphasizing how these biological indicators can enhance clinical practices